Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Long-Term Use of Topical Treatments in Atopic Dermatitis
Panelists discuss how the newer topical agents (PDE4 inhibitors, JAK inhibitors) demonstrate comparable efficacy to midpotency corticosteroids but with improved safety profiles, lacking steroid-related adverse effects such as skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and tachyphylaxis when used long term.
EP: 1.Diagnosing and Defining Severity of Atopic Dermatitis
EP: 2.Older Approaches to Topical Treatment of Atopic Dermatitis
EP: 3.New Nonsteroidal Topical Treatment Options for Atopic Dermatitis
Now Viewing
EP: 4.Long-Term Use of Topical Treatments in Atopic Dermatitis
EP: 5.Addressing Itch and Quality of Life for Patients With Atopic Dermatitis
EP: 6.Importance of Patient Education and Multidisciplinary Communication
Video content above is prompted by the following:
- How do the long-term efficacy and safety profiles of these newer agents compare with topical corticosteroids?
Related Videos
Related Content
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025Article
RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
